Nycomed and VHA sign five-year deal

Article

Nycomed has secured a five-year agreement with VHA, the nation's largest health-care network,to provide its nonionic imaging agent Omnipaque (iohexol) underthe VHA Plus label. It is the second such contract signed recently by Nycomed andVHA. In October

Nycomed has secured a five-year agreement with VHA, the nation's largest health-care network,to provide its nonionic imaging agent Omnipaque (iohexol) underthe VHA Plus label.

It is the second such contract signed recently by Nycomed andVHA. In October 1994, the companies agreed to a three-year pactpermitting VHA Plus labeling of Omniscan (gadodiamide), a nonionicMRI imaging agent.

The private labeling deal permits VHA to market the agentsto its network of 1132 health-care organizations, which representnearly one of five U.S. hospitals. The network purchases $6 billionworth of supplies and services annually through VHA contracts,Nycomed officials said.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
CT-Based Deep Learning Model May Reduce False Positives with Indeterminate Lung Nodules by Nearly 40 Percent
Leading Breast Radiologists Discuss Rise of Breast Cancer Incidence in Women Under 40
New Research Examines Radiation Risks with CT Exposure Prior to Pregnancy
© 2025 MJH Life Sciences

All rights reserved.